Artemis Medicare Services Limited has informed the Exchange about Investor Presentation
ARTEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Artemis Medicare Services submitted its Q4 and FY2025 earnings presentation to the exchanges. For FY25, consolidated gross revenue rose 6.5% YoY to Rs 9,819 Mn, while EBITDA jumped 31.9% to Rs 1,848 Mn, lifting EBITDA margin to 19.7% from 15.9%. PAT grew 67.2% to Rs 822 Mn. Q4 FY25 also showed strong growth with EBITDA margin at 20.1% (vs 17.7%) and PAT up 60.3% YoY. The company raised Rs 330 Cr from IFC to fund expansion, opened a third tower at Gurgaon taking capacity to 700+ beds, and announced a 300+ bed super-speciality hospital in Raipur along with plans for Tier 2 cities and overseas (Artemis Curepipe Hospital in Mauritius). Cash and bank balances surged to Rs 3,932 Mn (standalone) from Rs 580 Mn.
Significant margin expansion and strong PAT growth signal improving operational leverage, which is positive for shareholders. The Rs 330 Cr IFC raise and multi-pronged expansion (Raipur, Tier 2 cities, overseas) point to a clear growth runway, though increased capex and debt may pressure near-term returns. Overall, the strong earnings beat and visible expansion pipeline are likely to be viewed favorably by the market.